📰 Dror Bashan News
Page 4 - Dror Bashan News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dror Bashan. Real-time updates on events, politics, business and more.
December 21, 2022
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
December 21, 2022
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
December 1, 2022
EQS-News: Protalix BioTherapeautics Inc. Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment 30.11.2022 / 21:00 CET/CEST The issuer is solely responsible for the content of this announcement. Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical co...
November 30, 2022
30.11.2022 - EQS-News: Protalix BioTherapeautics Inc. Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment 30.11.2022 / 21:00 CET/CEST The issuer is solely responsible for the content of this announcement. Protalix BioTherapeutics, Inc. (NYSE ... Seite 1
November 30, 2022
EQS-News: Protalix BioTherapeautics Inc. Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment 30.11.2022 / 21:00 CET/CEST The issuer is solely responsible for the content
November 15, 2022
Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results - read this article along with other careers information, tips and advice on BioSpace
November 14, 2022
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
September 6, 2022
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
June 17, 2022
Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX – Get Rating) saw a significant drop in short interest in May. As of May 31st, there was short interest totalling 2,740,000 shares, a drop of 27.7% from the May 15th total of 3,790,000 shares. Based on an average daily trading volume, of 3,700,000 shares, the short-interest ratio is presently 0.7 […]
June 1, 2022
Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX – Get Rating) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 3,790,000 shares, a decrease of 16.3% from the April 30th total of 4,530,000 shares. Approximately 9.9% of the shares of the stock are sold short. Based on […]